ClinicalTrials.gg
TerminatedNCT03389893Updated Oct 4, 2021Results posted

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

A Phase 4 interventional study of Dupilumab and Placebo in Atopic Dermatitis (AD), sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Terminated at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-10-04.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 4, Interventional, and Treatment

Why this study was terminated
Due to inability to meet accrual goals within the funding period.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
26th of 50
72 · median 75
Started
2018
with 4 others
Phase 4
24 of 50
4 open now
Registered
21st of 50
by date
Lead sponsor
2 of 50
National Institute of Allergy and Infectious Diseases (NIAID)

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 26th largest by enrollment, is one of 5 that started in 2018, is one of 24 in phase 4, and was the 21st registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to understand the effect that T helper 2 (Th2) blockade has on well-described pathophysiological features of Atopic Dermatitis (AD), for example: barrier, epidermal activation, dysbiosis and epidermal lipids.

Read the detailed description

This is a multi-center, randomized, double-masked, placebo-controlled trial investigating the effect of 6 weeks of dupilumab treatment on quantitative and qualitative measures of cutaneous microbial community structure, skin barrier biology, and circulating T cell profiles, in adults with chronic moderate-to-severe atopic dermatitis (AD).

After obtaining informed consent, eligible participants will return to clinic for their Treatment Initiation Visit (Day 0) and will be randomized 2:1 active to placebo. Participants will receive three doses of dupilumab or placebo based on their randomization assignment. The first dose (600 mg loading dose of dupilumab or placebo) will be administered on Day 0 and the second and third doses (300 mg dupilumab or placebo) on Day 14 and Day 28, respectively.

Participants will return to clinic on Days 3, 7, and 21 during the double-masked portion of the study. Participants will begin the open-label extension (OLE) at Day 42 and will receive dupilumab (600 mg loading dose [two 300 mg injections] for those initially randomized to the placebo group and a 300 mg dose plus placebo injection for those initially randomized to the dupilumab group). Participants will return to clinic on Days 77 and 112 during the OLE portion of the study. During all visits (Day 0-Day 112), Adverse Events (AEs), concomitant medications, and medical history will be assessed and physical exams including assessment of AD severity will be performed. Blood, urine, skin swabs, skin tape strips, and skin biopsies, as applicable, will be collected, and barrier assessments will be performed per the Schedule of Events, per protocol. Samples will be collected prior to dupilumab or placebo administration on Days 0, 14, 28, and 42. After Day 112, a follow-up call (Day 182) will be made to assess for pregnancy, current medications, and adverse events (AEs).

If concerns arise between regularly scheduled visits, participants will be instructed to contact study personnel and may be asked to return to the study site for an "Unscheduled Visit." Participants may be asked to return for Unscheduled Visits, as needed for the duration of the study, to provide additional blood, skin swabs, skin tape strips, or skin biopsies,as applicable, for further mechanistic and functional studies, if biosamples are lost or destroyed, or if insufficient yields were obtained at a previous study visit.

03

Conditions studied

  • Atopic Dermatitis (AD)

Browse trials for

Keywords

  • randomized double-masked (blind) placebo-controlled trial
  • T helper 2 (Th2) effect
  • cutaneous microbial community
  • skin barrier
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be able to understand and provide
  • Chronic AD, (according to the Atopic Dermatitis Research Network [ADRN] Standard Diagnostic Criteria), that has been present for at least 3 years before the Screening Visit
  • EASI score ≥12 at the Screening Visit and ≥16 at the Treatment Initiation Visit
  • Investigator Global Assessment (IGA) score ≥3 (on the 0-4 IGA scale) at the Screening and Treatment Initiation Visits
  • ≥10% body surface area of AD involvement at the Screening and Treatment Initiation Visits
  • Must have active lesions (minimum of 3 of at least 4x4 cm\^2 each on the upper or lower extremities, excluding the palms of the hands and soles of the feet) at the Screening and Treatment Initiation Visits
  • Documented recent history (within 6 months before the Screening Visit) of inadequate response to outpatient treatment with topical of medium to high potency (± topical calcineurin inhibitors as appropriate), or for whom topical treatments are otherwise inadvisable
  • Must agree to apply a stable dose of a topical emollient (moisturizer) at least twice daily for at least 7 days before the Treatment Initiation Visit, and must confirm application at the Treatment Initiation Visit
  • Individuals with asthma must adhere to asthma controller medication(s) for the duration of the study including the open-label and follow-up portions
  • Females of must have a negative pregnancy test at the Screening and Treatment Initiation Visits
  • Females with * and sexually active must agree to use FDA approved methods of for the duration of the study, including during the open-label and follow-up portions of the study:

    --FDA approved methods of birth control include hormonal contraceptives, intrauterine device, double barrier contraception (i.e., condom plus diaphragm), or male partner with documented vasectomy.

    ---*Menopause is defined as at least 12 consecutive months without menses; if in question, a follicle stimulating hormone of ≥25 U/mL must be documented. Hysterectomy, bilateral oophorectomy, or bilateral tubal ligation must be documented, as applicable; if documented, women with these conditions are not required to use additional contraception.

  • Males who are sexually active must agree to use an acceptable method of birth control (e.g. barrier methods with vaginal spermicide, surgical sterilization or surgically sterilized partner), or have a female partner practicing an approved birth control method for females as described in Inclusion Criterion above.
  • Willing and able to comply with all clinic visits and study-related procedures
  • Able to understand and complete study-related questionnaires

Exclusion criteria

Exclusion Criteria:

  • Inability or unwillingness of an individual to give written or comply with study protocol
  • Known systemic to any of the of the dupilumab or placebo study products
  • Known or suspected , including history of invasive opportunistic infections (e.g., tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent immune-compromised status, as judged by the investigator
  • Known history of (HIV) infection
  • Ocular disorder that, in the opinion of the investigator, could adversely affect the individual's risk for study participation. Examples include, but are not limited to, individuals with a history of or active case of:

    • herpes keratitis,
    • Sjogren's Syndrome,
    • keratoconjunctivitis sicca or Dry Eye Syndrome that requires daily use of supplemental lubrication, or
    • ocular condition(s) requiring the regular use of ocular or cyclosporine.
  • Parasitic infection, except for vaginal trichomoniasis, within 12 months of the Treatment Initiation Visit, or high risk for contracting parasitic infections (e.g., living in or traveling to endemic areas)
  • Presence of skin comorbidities that may interfere with study assessments
  • History of within 5 years before the Treatment Initiation Visit except completely treated in situ carcinoma of the cervix, and completely treated and resolved non- squamous or basal cell carcinoma of the skin or melanoma in situ
  • History of non-malignant lymphoproliferative disorders
  • History of alcohol or drug abuse within 2 years before the Screening Visit
  • Severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the individual's participation in the study. Examples include, but are not limited to, individuals with short , uncontrolled diabetes ( ≥9%), cardiovascular conditions (e.g., stage III or IV cardiac failure according to the classification), severe renal conditions (e.g., individuals on dialysis), hepato-biliary conditions (e.g., class B or C), neurological conditions (e.g., demyelinating diseases), active major diseases (e.g., lupus, inflammatory bowel disease, rheumatoid arthritis, etc.), other severe endocrinological, gastrointestinal, metabolic, pulmonary, or lymphatic diseases.
  • Any other medical or psychological condition including relevant laboratory abnormalities at screening that, in the opinion of the investigator, suggests a new and/or insufficiently understood disease, may present an unreasonable risk to the study participant as a result of his/her participation in this clinical trial, may make individual's participation unreliable, or may interfere with study assessments. This includes hypersensitivity to local anesthetics (e.g., lidocaine or Novocain), bleeding disorders, treatment with anticoagulants or other conditions that make the procedure inadvisable.
  • Planned major surgical procedure during the screening period or study treatment (i.e. Screening through Day 112)
  • Member of the team or his/her immediate family
  • Pregnant or breast-feeding women, or women planning to become pregnant or breastfeed during the study including the open-label and follow up portions of the study
  • Individuals unwilling to use adequate , if of and sexually active. Adequate birth control is defined as agreement to consistently practice an approved method of contraception for the duration of the study, including the open-label and follow up portions of the study.
  • History of keloid formation
  • History of serious life-threatening reaction to latex, tape, or adhesives
  • Prior treatment with dupilumab
  • Individuals with asthma who have required use of a systemic corticosteroid within 3 months prior to the Treatment Initiation Visit or who require a dose greater than 880 mcg/day of fluticasone propionate or equivalent inhaled corticosteroid to maintain asthma control
  • Treatment with biologics as follows:

    • Any cell-depleting agents, including but not limited to rituximab, within 6 months before the Treatment Initiation Visit, or until lymphocyte and CD 19+ lymphocyte count returns to normal, whichever is longer
    • Infliximab, adalimumab, golimumab, certolizumab pegol, abatacept, etanercept, anakinra within 16 weeks before the Treatment Initiation Visit for any indication, or
    • Other biologics within 5 half-lives (if known) or 16 weeks before the Treatment Initiation Visit, whichever is longer
  • Treatment with a live (attenuated) vaccine within 12 weeks before the Treatment Initiation Visit or planning to receive a during the study (through Day 182)
  • Use of an investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer, before the Treatment Initiation Visit
  • Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks before the Treatment Initiation Visit, or superficial skin infections within 1 week before the Treatment Initiation Visit
  • The following treatments within 4 weeks before the Treatment Initiation Visit, or any condition that, in the opinion of the investigator, will likely require such treatment(s) during the screening period and study treatment (i.e., Screening through Day 112):

    • Systemic corticosteroids
    • Immunosuppressive/immunomodulating drugs (e.g., cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, or methotrexate)
  • Use of phototherapy (such as narrow band ultraviolet B [NBUVB], ultraviolet B [UVB], ultraviolet A1 [UVA1], psoralen + UVA [PUVA]) or a tanning booth/parlor within 4 weeks of the Treatment Initiation Visit
  • Treatment with bleach bath within 3 weeks before the Treatment Initiation Visit
  • Use of a chlorinated hot tub within 3 weeks before the Treatment Initiation Visit
  • Treatment with topical corticosteroids, phosphodiesterase inhibitors (crisaborole), or calcineurin inhibitors (tacrolimus or pimecrolimus) within 1 week before the Treatment Initiation Visit
  • Initiation of treatment of AD with prescription moisturizers or moisturizers containing ceramide, hyaluronic acid, urea, or filaggrin during the screening period (participants may continue using stable doses of such moisturizers if initiated before the Screening Visit)
  • Planned or anticipated use of any prohibited medications or procedures during the screening period and study treatment (i.e., Screening through Day 112)
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Dupilumab w/OLE

    Participants will receive a loading dose of dupilumab (two 300 mg subcutaneous (subcut) injections (total of 600 mgs)) on Day 0, followed by 300 mg dose of dupilumab by subcut injection every 2 weeks (Days 14 and 28). Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of two subcut administered injections (one 300 mg dose of dupilumab and one dose of placebo, in order to protect prior masking/blind).Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98. The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose.

    Drug: Dupilumab · Drug: Placebo

  • Placebo comparator
    Placebo Comparator w/OLE

    Participants will receive a loading dose of placebo (two placebo subcutaneous (subcut) injections) on Day 0 followed by one dose of placebo by subcut injections every 2 weeks (Days 14 and 28). Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of dupilumab (two 300 mg subcut injections (total of 600 mgs)-protection of prior masking/blind maintained). Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98. The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose.

    Drug: Dupilumab · Drug: Placebo

Interventions

  • Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)

    Also known as: Dupixent®, IL4Ra mAb

  • DrugPlacebo

    Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.

    Also known as: Dupilumab placebo

06

What researchers measure

Primary outcomes

  1. Staphylococcus Aureus Abundance on Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

    Staphylococcus aureus (S. aureus) abundance was measured by microbial DNA (femA qPCR) on lesional skin at Day 28, measurement is expressed in relative Colony Forming Units (rCFU)/cm\^2). The abundance of S. aureus is summarized as the geometric mean ratio (and corresponding 95% confidence interval) between the dupilumab and placebo arms. The geometric mean ratio is reported from an ANCOVA model with fixed effects for clinical site, disease severity at Day 0 (as measured by EASI \>21.1 \[severe\] or ≤21.1 \[non-severe\]) and S. aureus abundance at Day 0.

    Time frame: Day 28 (Post treatment initiation)

Secondary outcomes

  1. Staphylococcus Aureus Abundance on Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

    Staphylococcus aureus (S. aureus) abundance was measured by microbial DNA (femA qPCR) on lesional skin at Days 0, 3, 7, 14, 21, 42, 77 and 112. The abundance of S. aureus is summarized as the geometric mean ratio (GMR) and corresponding 95% confidence interval between the dupilumab and placebo arms. The GMR is reported from a linear mixed model for repeated measures with fixed effects for S. aureus abundance on lesional skin at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement (as a categorical variable), and an interaction term between treatment arm and pre-specified time point(s). A linear mixed model similar to the model specified above was fit for every time point measured. The model was used to estimate the GMR between treatment arms at Days 77 and 112 and the ratio within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.

    Time frame: Day 0 (Prior to treatment), 3, 7, 14, 21, 42, 77 and 112

  2. Staphylococcus Aureus Abundance on Non-lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

    Staphylococcus aureus (S. aureus) abundance was measured by microbial DNA (femA qPCR) on non-lesional skin at Days 0, 3, 7, 14, 21, 28, 42, 77 and 112. The abundance of S. aureus is summarized as the geometric mean ratio (GMR) and corresponding 95% confidence interval between the dupilumab and placebo arms. The GMR is reported from a linear mixed model for repeated measures with fixed effects for S. aureus abundance on non-lesional skin at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement (as a categorical variable), and an interaction term between treatment arm and pre-specified time point(s). A linear mixed model similar to the model specified above was fit for every time point measured. The model estimated the GMR between treatment arms at Days 77 and 112 and the ratio within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.

    Time frame: Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112

  3. Transepidermal Water Loss (TEWL) of Non-lesional and Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

    TEWL assessment is a noninvasive in vivo measurement of water loss across the stratum corneum that is used to characterize skin barrier function. Basal TEWL =baseline measure (prior to tape stripping). An increase in TEWL values shows damage to the skin barrier function. Basal TEWL was measured on non-lesional and lesional skin. Basal TEWL is summarized as the mean difference between the dupilumab and placebo arms. The mean difference is reported from two linear mixed models for repeated measures (lesional and non-lesional) with fixed effects for treatment arm, basal TEWL at Day 0, clinical site, and disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1 at Days 3, 7, 14, 21, 28, and 42. Two linear mixed models similar to the models specified above were fit for every time point measured. The model was used to estimate the mean difference between treatment arms at Days 77 and 112 and the ratio within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.

    Time frame: Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112

  4. Transepidermal Water Loss (TEWL) Area Under the Curve (AUC) on Non-Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

    TEWL skin barrier assessment was assessed prior to tape stripping and repeated after 5, 10, and 15 tape strips. TEWL AUC was calculated using the trapezoidal rule and represents skin barrier integrity. An increase in TEWL values shows damage to the skin barrier function. TEWL AUC was measured on non-lesional skin at Days 0, 7, 14, 21, 28, 42, 77 and 112. The mean difference (between Groups) is reported from a linear mixed model for repeated measures with a random effect for participant and fixed effects for treatment arm, TEWL AUC at Day 0, clinical site, and disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1 at Days 7, 14, 21, 28, and 42. A linear mixed model similar to the model specified above was fit for every time point measured. The model was used to estimate the mean difference between treatment arms at Days 77 and 112 and the mean difference within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.

    Time frame: Day 0 (Prior to treatment), 7, 14, 21, 28, 42, 77 and 112

  5. Transepidermal Water Loss (TEWL) Slope on Non-Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

    The skin tape strip collection was comprised of 1 set of 15 strips from non-lesional skin and was collected as part of the TEWL skin barrier assessment. The TEWL values measured at every 5 tape strips were used to model the TEWL slope. TEWL slope assesses skin barrier integrity. An increase in TEWL values shows damage to the skin barrier function. TEWL slope is summarized as the mean difference (and corresponding 95% confidence interval) between the dupilumab and placebo arms. The mean difference in slope for each Day is reported from a linear mixed model for repeated measures with a fixed effects for basal TEWL prior to tape stripping, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, tape strip number, and an interaction term between treatment arm and tape strip number.

    Time frame: Day 0 (Prior to treatment), 7, 14, 21, 28, 42, 77 and 112

  6. Eczema Area and Severity Index (EASI) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

    EASI is a composite score (range: 0-72) measuring physical signs of atopic dermatitis, including area of involvement and severity. Severity components include: erythema, papulation, excoriation and lichenification \[0=absent, 1=mild, 2=moderate, 3=severe\] for each body region (head/neck, trunk, arms, legs). Area of involvement (%) is assessed for each body region. Area and severity of each body region is weighted based on size of region, and region scores are added for the total score. Scores ≤7 are considered mild, \>7 and ≤21 are considered moderate, and \>21 are considered severe. The mean EASI score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for EASI at Day 0, treatment arm, clinical site, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s), Additionally, a similar model was fit using all time points.

    Time frame: Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112

  7. Investigator Global Assessment (IGA) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

    Investigator Global Assessment (IGA) score is a subjective scale measuring disease severity. Based on a 5-point scale from 0 (completely clear) to 4 (severe). Defined score of 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe. The mean IGA score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for IGA at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s). Additionally, a similar model was fit using all time points.

    Time frame: Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112

  8. SCORing Atopic Dermatitis (SCORAD) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

    SCORAD is a composite index comprising a) the amount/extent of body surface area affected, b) subjective symptom visual analog assessments of itch and sleep loss \[itch: 0 (no itch) to 10 (worst itch imaginable) / sleep loss: 0 (no sleep loss) to 10 (worst imaginable sleep loss)\], and c) 6 disease intensity assessments \[dryness, erythema, edema/papulation, excoriation, lichenification and oozing/crusting, each graded from 0-3: 0 (none), 1 (mild), 2 (moderate) and 3 (severe). The score ranges from 0 (no AD present) to 103 (severe). The mean SCORAD score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for SCORAD at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s). Additionally, a similar model was fit using all time points.

    Time frame: Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112

  9. Pruritus Numerical Rating Scale (Pruritus NRS) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

    Pruritus NRS scale is an assessment tool that is used to report the average intensity of a participant's pruritus (itch) during a 24-hour recall period. Participants were asked to report the average itch experienced during the past 24 hours on a scale of 0 - 10 \[0= no itch; 10= worst imaginable itch\]). The mean Pruritus NRS score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for Pruritus NRS at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s). Additionally, a similar model was fit using all time points.

    Time frame: Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112

Other outcomes

  1. EXPLORATORY: Composition of Bacterial Taxa

    16S rRNA microbiome data (e.g., bacterial sequence reads) will be employed to identify changes in community composition and diversity at lesional and non-lesional skin sites prior to and throughout dupilumab or placebo treatment.

    Time frame: Day 0 (Prior to treatment), 16 weeks

  2. EXPLORATORY: Abundance of Bacterial Taxa in Lesional and Non-lesional Skin

    The aim is to assess the effect of dupilumab on the skin transcriptome in lesional and non-lesional skin. Inclusion in this exploratory aim is restricted to non-University of Rochester Medical Center study participants only.

    Time frame: Day 0 (Prior to treatment), 16 weeks

  3. EXPLORATORY: Gene Expression in the Skin Transcriptome in Non-lesional Skin

    The aim is to assess the effect of dupilumab on gene expression in the skin transcriptome of non-lesional skin.

    Time frame: Day 0 (Prior to treatment) and 7

  4. EXPLORATORY: Gene Expression in the Skin Transcriptome in Lesional Skin

    The aim is to assess the effect of dupilumab on the gene expression in the skin transcriptome of lesional skin.

    Time frame: Day 0 (Prior to treatment), 7, and 21

  5. EXPLORATORY: Lipid Profiles of Non-Lesional and Lesional Skin

    The aim is to assess the effect of dupilumab on lipids, which play a role in the skin barrier, will be extracted from the skin tape strips and measured using mass spectrometry methodology. Skin tape strip method allows characterization of components of the epidermis, dermis, and immune cells present in the skin.

    Time frame: Day 0 (Prior to treatment), 16 weeks

  6. EXPLORATORY: Expression of S. Aureus Superantigens and Toxins on Lesional and Non-Lesional Skin

    The aim is to assess the effect of dupilumab on the expression of the bacterium Staphylococcus aureus (S. aureus) superantigens and toxins on lesional and non-lesional skin.

    Time frame: Day 0 (Prior to treatment), 16 weeks

  7. EXPLORATORY: Confocal Imaging of Tight Junctions and Relationship to LCs in the Epidermis From Non-Lesional Skin

    The aim is to assess the effect of dupilumab on non-lesional skin barrier structure and Langerhans cells (LC) by confocal imaging. Inclusion in this exploratory aim is limited to University of Rochester Medical Center study participants.

    Time frame: Days 0 (Prior to treatment), 7 and 21

  8. EXPLORATORY: Percent of Coagulase-Negative Staphylococci [CoNS] Isolates That Kill S. Aureus on Lesional and Non-Lesional Skin

    The aim is to assess the effect of dupilumab on the function of the skin microbiome (e.g., the ability of Coagulase-negative staphylococci isolates \[CoNS\] to kill S. aureus) in lesional and non-lesional skin.

    Time frame: Day 0 (Prior to treatment), 16 weeks

  9. EXPLORATORY: Peripheral Blood Mononuclear Cells (PBMCs) Immunoprofiling

    The aim is to assess the effect of dupilumab on PBMC immunoprofiles.Flow cytometry analysis will be performed on PBMCs, using phenotyping panels to identify resting leukocyte populations, as well as T cell responses to antigens and myeloid responses to Toll-like receptor (TLR) ligands.

    Time frame: Days 0 (Prior to treatment), 14 and 28

  10. EXPLORATORY: Levels of Serum Biomarkers (e.g. Th2 Biomarkers)

    The aim is to assess the effect of dupilumab on serum biomarkers (e.g. T helper type 2 \[Th2\] biomarkers).

    Time frame: Day 0 (Prior to treatment), 16 weeks

  11. EXPLORATORY: Levels of Serum Anti-Drug Antibodies (ADA)

    The presence of anti-drug antibodies will be assessed and compared between intervention groups.

    Time frame: Day 0 (Prior to treatment), 16 weeks

  12. EXPLORATORY: The Presence of Single Nucleotide Polymorphisms (SNPs)

    Towards discovery and replication of susceptibility loci in atopic dermatitis pathogenesis.

    Time frame: Day 0 (Prior to treatment)

07

Results

Posted Jun 14, 2021
Limitations and caveats
One randomized participant did not meet criteria to be in the modified intent-to-treat (mITT) population because they withdrew prior to Day 28. Ten participants had 23 modified visits due to the coronavirus disease 2019 (COVID-19) pandemic.

Participant flow

72 participants were randomized from July 2018 to March 2020 from 9 clinical sites.First participant enrollment occurred on July 25, 2018.

Randomized Double Blind Period
Participant flow — Randomized Double Blind Period
MilestoneDupilumabPlaceboDupilumab to Open-Label Extension DupilumabPlacebo to Open-Label Extension Dupilumab
Started462600
Completed452600
Not completed1000
Withdrew: Withdrawal by subject1000
Open Label Extension and Follow-Up
Participant flow — Open Label Extension and Follow-Up
MilestoneDupilumabPlaceboDupilumab to Open-Label Extension DupilumabPlacebo to Open-Label Extension Dupilumab
Started004526
Completed004125
Not completed0041
Withdrew: Lost to follow-up0021
Withdrew: Physician decision0010
Withdrew: Participant moved0010

Outcome measures

PrimaryStaphylococcus Aureus Abundance on Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

Staphylococcus aureus (S. aureus) abundance was measured by microbial DNA (femA qPCR) on lesional skin at Day 28, measurement is expressed in relative Colony Forming Units (rCFU)/cm\^2). The abundance of S. aureus is summarized as the geometric mean ratio (and corresponding 95% confidence interval) between the dupilumab and placebo arms. The geometric mean ratio is reported from an ANCOVA model with fixed effects for clinical site, disease severity at Day 0 (as measured by EASI \>21.1 \[severe\] or ≤21.1 \[non-severe\]) and S. aureus abundance at Day 0.

Time frame:
Day 28 (Post treatment initiation)
Reported as:
Geometric mean · Relative Colony Forming Unit (rCFU)/cm^2
Staphylococcus Aureus Abundance on Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
Relative Colony Forming Unit (rCFU)/cm^2Dupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-Up
Staphylococcus Aureus Abundance on Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up86.01 (34.07 to 217.11)2608.4 (835.02 to 8147.99)
Statistical analysis
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · ANCOVA · p = <0.001 · Geometric mean ratio: 0.033 · 95% CI 0.008 to 0.131Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator.
SecondaryStaphylococcus Aureus Abundance on Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

Staphylococcus aureus (S. aureus) abundance was measured by microbial DNA (femA qPCR) on lesional skin at Days 0, 3, 7, 14, 21, 42, 77 and 112. The abundance of S. aureus is summarized as the geometric mean ratio (GMR) and corresponding 95% confidence interval between the dupilumab and placebo arms. The GMR is reported from a linear mixed model for repeated measures with fixed effects for S. aureus abundance on lesional skin at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement (as a categorical variable), and an interaction term between treatment arm and pre-specified time point(s). A linear mixed model similar to the model specified above was fit for every time point measured. The model was used to estimate the GMR between treatment arms at Days 77 and 112 and the ratio within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.

Time frame:
Day 0 (Prior to treatment), 3, 7, 14, 21, 42, 77 and 112
Reported as:
Geometric mean · Relative Colony Forming Unit (rCFU)/cm^2
Staphylococcus Aureus Abundance on Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
Relative Colony Forming Unit (rCFU)/cm^2Dupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-Up
Day 3833.82 (411.45 to 1689.74)3028.88 (1256.63 to 7300.56)
Day 7337.48 (138.69 to 821.16)900.59 (290.95 to 2787.59)
Day 14205.06 (91.16 to 461.27)2690.79 (964.61 to 7505.96)
Day 21179.91 (80.71 to 401.02)2468.64 (916.89 to 6646.62)
Day 42177.79 (79.02 to 400.05)1112.55 (409.02 to 3026.14)
Day 7756.85 (20.44 to 158.08)150.81 (43.93 to 517.81)
Day 11242.35 (14.91 to 120.28)174.19 (53.18 to 570.53)
Statistical analysis
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.019 · Geometric mean ratio: 0.28 · 95% CI 0.09 to 0.80Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.165 · Geometric mean ratio: 0.37 · 95% CI 0.09 to 1.51Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = <0.001 · Geometric mean ratio: 0.08 · 95% CI 0.02 to 0.27Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = <0.001 · Geometric mean ratio: 0.07 · 95% CI 0.02 to 0.25Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.004 · Geometric mean ratio: 0.16 · 95% CI 0.05 to 0.55Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.216 · Geometric mean ratio: 0.38 · 95% CI 0.08 to 1.80Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.071 · Geometric mean ratio: 0.24 · 95% CI 0.05 to 1.13Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.022 · Geometric mean ratio: 0.34 · 95% CI 0.13 to 0.85Day 77 is numerator and Day 42 is denominator
  • Dupilumab+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.015 · Geometric mean ratio: 0.25 · 95% CI 0.08 to 0.76Day 112 is numerator and Day 42 is denominator
  • Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = <0.001 · Geometric mean ratio: 0.14 · 95% CI 0.04 to 0.41Day 77 is numerator and Day 42 is denominator
  • Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.006 · Geometric mean ratio: 0.16 · 95% CI 0.04 to 0.58Day 112 is numerator and Day 42 is denominator
SecondaryStaphylococcus Aureus Abundance on Non-lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

Staphylococcus aureus (S. aureus) abundance was measured by microbial DNA (femA qPCR) on non-lesional skin at Days 0, 3, 7, 14, 21, 28, 42, 77 and 112. The abundance of S. aureus is summarized as the geometric mean ratio (GMR) and corresponding 95% confidence interval between the dupilumab and placebo arms. The GMR is reported from a linear mixed model for repeated measures with fixed effects for S. aureus abundance on non-lesional skin at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement (as a categorical variable), and an interaction term between treatment arm and pre-specified time point(s). A linear mixed model similar to the model specified above was fit for every time point measured. The model estimated the GMR between treatment arms at Days 77 and 112 and the ratio within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.

Time frame:
Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112
Reported as:
Geometric mean · Relative Colony Forming Unit (rCFU)/cm^2
Staphylococcus Aureus Abundance on Non-lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
Relative Colony Forming Unit (rCFU)/cm^2Dupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-Up
Day 3221.75 (99.74 to 493.01)277.21 (100.25 to 766.52)
Day 7143.19 (66.56 to 308.04)539.97 (201.61 to 1446.22)
Day 14118.15 (57.86 to 241.27)326.55 (132.38 to 805.48)
Day 2193.32 (44.33 to 196.46)128.56 (51.17 to 323.01)
Day 2861.67 (29.55 to 128.72)369.74 (145.96 to 936.60)
Day 4298.97 (44.01 to 222.55)191.30 (70.36 to 520.10)
Day 7786.91 (32.27 to 234.09)182.19 (57.37 to 578.60)
Day 11276.71 (27.37 to 214.99)146.35 (45.23 to 473.54)
Statistical analysis
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.724 · Geometric mean ratio: 0.80 · 95% CI 0.23 to 2.82Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.033 · Geometric mean ratio: 0.27 · 95% CI 0.08 to 0.89Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.073 · Geometric mean ratio: 0.36 · 95% CI 0.12 to 1.10Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.579 · Geometric mean ratio: 0.73 · 95% CI 0.23 to 2.29Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.003 · Geometric mean ratio: 0.17 · 95% CI 0.05 to 0.53Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.297 · Geometric mean ratio: 0.52 · 95% CI 0.15 to 1.81Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.326 · Geometric mean ratio: 0.48 · 95% CI 0.11 to 2.12Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.401 · Geometric mean ratio: 0.52 · 95% CI 0.11 to 2.42Dupilumab+Open Label Extension and Follow-Up arm is numerator and Placebo+Open Label Extension and Follow-Up arm is denominator
  • Dupilumab+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.705 · Geometric mean ratio: 0.81 · 95% CI 0.28 to 2.40Day 77 is numerator and Day 42 is denominator
  • Dupilumab+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.538 · Geometric mean ratio: 0.72 · 95% CI 0.25 to 2.08Day 112 is numerator and Day 42 is denominator
  • Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.892 · Geometric mean ratio: 0.92 · 95% CI 0.25 to 3.34Day 77 is numerator and Day 42 is denominator
  • Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.624 · Geometric mean ratio: 0.74 · 95% CI 0.21 to 2.56Day 112 is numerator and Day 42 is denominator
SecondaryTransepidermal Water Loss (TEWL) of Non-lesional and Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

TEWL assessment is a noninvasive in vivo measurement of water loss across the stratum corneum that is used to characterize skin barrier function. Basal TEWL =baseline measure (prior to tape stripping). An increase in TEWL values shows damage to the skin barrier function. Basal TEWL was measured on non-lesional and lesional skin. Basal TEWL is summarized as the mean difference between the dupilumab and placebo arms. The mean difference is reported from two linear mixed models for repeated measures (lesional and non-lesional) with fixed effects for treatment arm, basal TEWL at Day 0, clinical site, and disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1 at Days 3, 7, 14, 21, 28, and 42. Two linear mixed models similar to the models specified above were fit for every time point measured. The model was used to estimate the mean difference between treatment arms at Days 77 and 112 and the ratio within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.

Time frame:
Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112
Reported as:
Mean · g/m^2/hour
Transepidermal Water Loss (TEWL) of Non-lesional and Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
g/m^2/hourDupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-Up
Day 3 - Lesional33.46 (28.52 to 38.39)42.99 (36.57 to 49.41)
Day 7 - Lesional40.08 (33.79 to 46.37)41.15 (32.70 to 49.61)
Day 14 - Lesional31.96 (27.19 to 36.74)31.49 (25.47 to 37.51)
Day 21 - Lesional28.14 (23.25 to 33.02)34.11 (27.74 to 40.48)
Day 28 - Lesional24.93 (19.97 to 29.89)32.03 (25.93 to 38.13)
Day 42 - Lesional25.34 (20.58 to 30.10)33.33 (27.46 to 39.19)
Day 77 - Lesional24.54 (18.94 to 30.13)25.58 (19.14 to 32.02)
Day 112 - Lesional22.99 (16.79 to 29.18)22.82 (15.87 to 29.78)
Day 3 - Non-lesional24.24 (20.87 to 27.60)23.55 (19.05 to 28.05)
Day 7 - Non-lesional22.58 (19.60 to 25.57)20.23 (16.28 to 24.18)
Day 14 - Non-lesional23.30 (19.90 to 26.71)23.20 (18.77 to 27.63)
Day 21 - Non-lesional19.55 (16.54 to 22.57)22.86 (18.78 to 26.95)
Day 28 - Non-lesional17.55 (15.08 to 20.03)19.31 (16.11 to 22.51)
Day 42 - Non-lesional16.95 (14.50 to 19.40)19.12 (16.17 to 22.07)
Day 77 - Non-lesional15.45 (12.60 to 18.29)17.55 (14.27 to 20.82)
Day 112 - Non-lesional13.97 (11.55 to 16.39)15.86 (13.05 to 18.68)
Statistical analysis
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.019 · Mean difference (final values): -9.53 · 95% CI -17.44 to -1.63Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference.)
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.837 · Mean difference (final values): -1.08 · 95% CI -11.47 to 9.32Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.900 · Mean difference (final values): 0.47 · 95% CI -6.98 to 7.92Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.130 · Mean difference (final values): -5.97 · 95% CI -13.76 to 1.82Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.069 · Mean difference (final values): -7.10 · 95% CI -14.76 to 0.56Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.032 · Mean difference (final values): -7.99 · 95% CI -15.25 to -0.73Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.803 · Mean difference (final values): -1.05 · 95% CI -9.37 to 7.28Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.972 · Mean difference (final values): 0.16 · 95% CI -9.02 to 9.34Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.933 · Mean difference (final values): -0.27 · 95% CI -6.66 to 6.12Day 77 is minuend and Day 42 is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.563 · Mean difference (final values): -1.82 · 95% CI -8.10 to 4.45Day 112 is minuend and Day 42 is subtrahend. (Minuend - subtrahend=difference).
  • Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.075 · Mean difference (final values): -7.08 · 95% CI -14.88 to 0.73Day 77 is minuend and Day 42 is subtrahend. (Minuend - subtrahend=difference).
  • Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.010 · Mean difference (final values): -9.84 · 95% CI -17.19 to -2.48Day 112 is minuend and Day 42 is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.805 · Median difference (final values): 0.69 · 95% CI -4.86 to 6.23Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.329 · Mean difference (final values): 2.36 · 95% CI -2.44 to 7.15Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.970 · Mean difference (final values): 0.11 · 95% CI -5.39 to 5.60Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.180 · Mean difference (final values): -3.31 · 95% CI -8.18 to 1.56Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.342 · Mean difference (final values): -1.76 · 95% CI -5.45 to 1.94Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.234 · Mean difference (final values): -2.17 · 95% CI -5.81 to 1.47Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.316 · Mean difference (final values): -2.10 · 95% CI -6.27 to 2.07Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.276 · Mean difference (final values): -1.89 · 95% CI -5.37 to 1.59Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.237 · Mean difference (final values): -1.56 · 95% CI -4.19 to 1.06Day 77 is minuend and Day 42 is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.010 · Mean difference (final values): -3.03 · 95% CI -5.30 to -0.77Day 112 is minuend and Day 42 is subtrahend. (Minuend - subtrahend=difference).
  • Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.770 · Mean difference (final values): -0.46 · 95% CI -3.57 to 2.65Day 77 is minuend and Day 42 is subtrahend. (Minuend - subtrahend=difference).
  • Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.117 · Mean difference (final values): -2.14 · 95% CI -4.84 to 0.56Day 112 is minuend and Day 42 is subtrahend. (Minuend - subtrahend=difference).
SecondaryTransepidermal Water Loss (TEWL) Area Under the Curve (AUC) on Non-Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

TEWL skin barrier assessment was assessed prior to tape stripping and repeated after 5, 10, and 15 tape strips. TEWL AUC was calculated using the trapezoidal rule and represents skin barrier integrity. An increase in TEWL values shows damage to the skin barrier function. TEWL AUC was measured on non-lesional skin at Days 0, 7, 14, 21, 28, 42, 77 and 112. The mean difference (between Groups) is reported from a linear mixed model for repeated measures with a random effect for participant and fixed effects for treatment arm, TEWL AUC at Day 0, clinical site, and disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1 at Days 7, 14, 21, 28, and 42. A linear mixed model similar to the model specified above was fit for every time point measured. The model was used to estimate the mean difference between treatment arms at Days 77 and 112 and the mean difference within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.

Time frame:
Day 0 (Prior to treatment), 7, 14, 21, 28, 42, 77 and 112
Reported as:
Mean · g/m^2/hour
Transepidermal Water Loss (TEWL) Area Under the Curve (AUC) on Non-Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
g/m^2/hourDupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-Up
Day 7527.79 (466.25 to 589.33)442.74 (363.86 to 521.62)
Day 14504.80 (426.50 to 583.09)526.70 (424.66 to 628.74)
Day 21451.40 (385.72 to 517.07)533.89 (444.83 to 622.96)
Day 28390.92 (328.07 to 453.76)483.02 (405.23 to 560.81)
Day 42397.22 (341.24 to 453.20)445.98 (378.96 to 513.01)
Day 77363.15 (298.76 to 427.53)417.52 (344.23 to 490.81)
Day 112320.95 (266.16 to 375.74)343.92 (284.63 to 403.20)
Statistical analysis
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.085 · Mean difference (final values): 85.05 · 95% CI -12.02 to 182.12Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.733 · Mean difference (final values): -21.91 · 95% CI -149.13 to 105.32Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.129 · Mean difference (final values): -82.50 · 95% CI -189.60 to 24.61Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.057 · Mean difference (final values): -92.11 · 95% CI -187.11 to 2.89Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.242 · Mean difference (final values): -48.76 · 95% CI -131.52 to 34.00Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.262 · Mean difference (final values): -54.37 · 95% CI -150.24 to 41.49Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.546 · Mean difference (final values): -22.97 · 95% CI -99.79 to 53.86Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.503 · Mean difference (final values): -21.80 · 95% CI -86.34 to 42.75Day 77 is minuend and Day 42 is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.034 · Mean difference (final values): -64.00 · 95% CI -123.01 to -4.98Day 112 is minuend and Day 42 is subtrahend. (Minuend - subtrahend=difference).
  • Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.789 · Mean difference (final values): -10.29 · 95% CI -86.63 to 66.04Day 77 is minuend and Day 42 is subtrahend. (Minuend - subtrahend=difference).
  • Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.014 · Mean difference (final values): -83.90 · 95% CI -149.82 to -17.98Day 112 is minuend and Day 42 is subtrahend. (Minuend - subtrahend=difference).
SecondaryTransepidermal Water Loss (TEWL) Slope on Non-Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

The skin tape strip collection was comprised of 1 set of 15 strips from non-lesional skin and was collected as part of the TEWL skin barrier assessment. The TEWL values measured at every 5 tape strips were used to model the TEWL slope. TEWL slope assesses skin barrier integrity. An increase in TEWL values shows damage to the skin barrier function. TEWL slope is summarized as the mean difference (and corresponding 95% confidence interval) between the dupilumab and placebo arms. The mean difference in slope for each Day is reported from a linear mixed model for repeated measures with a fixed effects for basal TEWL prior to tape stripping, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, tape strip number, and an interaction term between treatment arm and tape strip number.

Time frame:
Day 0 (Prior to treatment), 7, 14, 21, 28, 42, 77 and 112
Reported as:
Number · g/m^2/hour
Transepidermal Water Loss (TEWL) Slope on Non-Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
g/m^2/hourDupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-Up
Day 71.77 (1.25 to 2.29)1.84 (1.18 to 2.51)
Day 141.56 (1.17 to 1.96)1.78 (1.28 to 2.28)
Day 211.43 (0.95 to 1.91)1.98 (1.37 to 2.60)
Day 281.38 (0.97 to 1.79)1.73 (1.23 to 2.23)
Day 421.47 (0.96 to 1.97)1.76 (1.15 to 2.37)
Day 771.15 (0.79 to 1.52)1.42 (0.99 to 1.85)
Day 1121.03 (0.70 to 1.36)1.30 (0.94 to 1.67)
Statistical analysis
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.860 · Slope: -0.07 · 95% CI -0.92 to 0.77Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.488 · Slope: -0.22 · 95% CI -0.85 to 0.41Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.144 · Slope: -0.55 · 95% CI -1.30 to 0.20Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.279 · Slope: -0.35 · 95% CI -1.00 to 0.30Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.461 · Slope: -0.29 · 95% CI -1.09 to 0.50Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.345 · Slope: -0.27 · 95% CI -0.84 to 0.30Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
  • Dupilumab+Open Label Extension and Follow-Up vs Placebo+Open Label Extension and Follow-Up · Mixed Models Analysis · p = 0.275 · Slope: -0.27 · 95% CI -0.77 to 0.23Dupilumab+Open Label Extension and Follow-Up arm is minuend and Placebo+Open Label Extension and Follow-Up arm is subtrahend. (Minuend - subtrahend=difference).
SecondaryEczema Area and Severity Index (EASI) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

EASI is a composite score (range: 0-72) measuring physical signs of atopic dermatitis, including area of involvement and severity. Severity components include: erythema, papulation, excoriation and lichenification \[0=absent, 1=mild, 2=moderate, 3=severe\] for each body region (head/neck, trunk, arms, legs). Area of involvement (%) is assessed for each body region. Area and severity of each body region is weighted based on size of region, and region scores are added for the total score. Scores ≤7 are considered mild, \>7 and ≤21 are considered moderate, and \>21 are considered severe. The mean EASI score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for EASI at Day 0, treatment arm, clinical site, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s), Additionally, a similar model was fit using all time points.

Time frame:
Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112
Reported as:
Mean · units on a scale
Eczema Area and Severity Index (EASI) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
units on a scaleDupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-Up
Day 326.52 (24.21 to 28.83)24.60 (21.73 to 27.46)
Day 725.96 (23.56 to 28.36)24.92 (21.92 to 27.91)
Day 1420.36 (17.92 to 22.81)23.13 (20.08 to 26.19)
Day 2116.57 (13.98 to 19.16)22.75 (19.51 to 25.98)
Day 2815.09 (12.47 to 17.72)21.67 (18.36 to 24.99)
Day 4211.90 (9.10 to 14.70)20.40 (16.83 to 23.96)
Day 778.84 (6.67 to 11.00)7.54 (4.89 to 10.19)
Day 1126.97 (5.19 to 8.76)5.53 (3.45 to 7.61)
SecondaryInvestigator Global Assessment (IGA) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

Investigator Global Assessment (IGA) score is a subjective scale measuring disease severity. Based on a 5-point scale from 0 (completely clear) to 4 (severe). Defined score of 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe. The mean IGA score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for IGA at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s). Additionally, a similar model was fit using all time points.

Time frame:
Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112
Reported as:
Mean · units on a scale
Investigator Global Assessment (IGA) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
units on a scaleDupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-Up
Day 33.49 (3.34 to 3.64)3.28 (3.09 to 3.47)
Day 73.32 (3.18 to 3.45)3.28 (3.11 to 3.45)
Day 143.12 (2.96 to 3.28)3.16 (2.96 to 3.37)
Day 212.86 (2.67 to 3.05)3.20 (2.96 to 3.44)
Day 282.72 (2.52 to 2.92)3.28 (3.02 to 3.54)
Day 422.58 (2.36 to 2.81)3.24 (2.95 to 3.53)
Day 772.20 (1.92 to 2.48)2.20 (1.84 to 2.55)
Day 1121.94 (1.63 to 2.24)1.89 (1.51 to 2.27)
SecondarySCORing Atopic Dermatitis (SCORAD) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

SCORAD is a composite index comprising a) the amount/extent of body surface area affected, b) subjective symptom visual analog assessments of itch and sleep loss \[itch: 0 (no itch) to 10 (worst itch imaginable) / sleep loss: 0 (no sleep loss) to 10 (worst imaginable sleep loss)\], and c) 6 disease intensity assessments \[dryness, erythema, edema/papulation, excoriation, lichenification and oozing/crusting, each graded from 0-3: 0 (none), 1 (mild), 2 (moderate) and 3 (severe). The score ranges from 0 (no AD present) to 103 (severe). The mean SCORAD score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for SCORAD at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s). Additionally, a similar model was fit using all time points.

Time frame:
Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112
Reported as:
Mean · units on a scale
SCORing Atopic Dermatitis (SCORAD) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
units on a scaleDupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-Up
Day 356.91 (53.46 to 60.35)53.12 (48.78 to 57.46)
Day 754.78 (51.70 to 57.86)54.96 (51.14 to 58.78)
Day 1446.55 (43.09 to 50.00)52.01 (47.66 to 56.73)
Day 2139.40 (35.53 to 43.28)51.87 (47.01 to 56.73)
Day 2836.34 (32.64 to 40.04)50.99 (46.33 to 55.66)
Day 4232.22 (28.38 to 36.06)51.02 (46.15 to 55.90)
Day 7727.63 (23.87 to 31.38)28.18 (23.53 to 32.83)
Day 11223.92 (20.25 to 27.59)25.01 (20.57 to 29.46)
SecondaryPruritus Numerical Rating Scale (Pruritus NRS) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up

Pruritus NRS scale is an assessment tool that is used to report the average intensity of a participant's pruritus (itch) during a 24-hour recall period. Participants were asked to report the average itch experienced during the past 24 hours on a scale of 0 - 10 \[0= no itch; 10= worst imaginable itch\]). The mean Pruritus NRS score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for Pruritus NRS at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s). Additionally, a similar model was fit using all time points.

Time frame:
Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112
Reported as:
Mean · units on a scale
Pruritus Numerical Rating Scale (Pruritus NRS) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
units on a scaleDupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-Up
Day 35.37 (4.73 to 6.01)5.64 (4.83 to 6.45)
Day 75.46 (4.83 to 6.09)5.48 (4.69 to 6.28)
Day 144.48 (3.91 to 5.05)5.29 (4.58 to 6.00)
Day 214.20 (3.62 to 4.79)5.22 (4.50 to 5.93)
Day 283.67 (3.07 to 4.28)5.14 (4.37 to 5.90)
Day 423.40 (2.79 to 4.01)5.18 (4.41 to 5.94)
Day 772.55 (2.05 to 3.05)1.88 (1.28 to 2.48)
Day 1122.38 (1.83 to 2.94)1.95 (1.27 to 2.64)
Other pre-specifiedEXPLORATORY: Composition of Bacterial Taxa

16S rRNA microbiome data (e.g., bacterial sequence reads) will be employed to identify changes in community composition and diversity at lesional and non-lesional skin sites prior to and throughout dupilumab or placebo treatment.

Time frame:
Day 0 (Prior to treatment), 16 weeks

Results for this outcome have not been posted.

Other pre-specifiedEXPLORATORY: Abundance of Bacterial Taxa in Lesional and Non-lesional Skin

The aim is to assess the effect of dupilumab on the skin transcriptome in lesional and non-lesional skin. Inclusion in this exploratory aim is restricted to non-University of Rochester Medical Center study participants only.

Time frame:
Day 0 (Prior to treatment), 16 weeks

Results for this outcome have not been posted.

Other pre-specifiedEXPLORATORY: Gene Expression in the Skin Transcriptome in Non-lesional Skin

The aim is to assess the effect of dupilumab on gene expression in the skin transcriptome of non-lesional skin.

Time frame:
Day 0 (Prior to treatment) and 7

Results for this outcome have not been posted.

Other pre-specifiedEXPLORATORY: Gene Expression in the Skin Transcriptome in Lesional Skin

The aim is to assess the effect of dupilumab on the gene expression in the skin transcriptome of lesional skin.

Time frame:
Day 0 (Prior to treatment), 7, and 21

Results for this outcome have not been posted.

Other pre-specifiedEXPLORATORY: Lipid Profiles of Non-Lesional and Lesional Skin

The aim is to assess the effect of dupilumab on lipids, which play a role in the skin barrier, will be extracted from the skin tape strips and measured using mass spectrometry methodology. Skin tape strip method allows characterization of components of the epidermis, dermis, and immune cells present in the skin.

Time frame:
Day 0 (Prior to treatment), 16 weeks

Results for this outcome have not been posted.

Other pre-specifiedEXPLORATORY: Expression of S. Aureus Superantigens and Toxins on Lesional and Non-Lesional Skin

The aim is to assess the effect of dupilumab on the expression of the bacterium Staphylococcus aureus (S. aureus) superantigens and toxins on lesional and non-lesional skin.

Time frame:
Day 0 (Prior to treatment), 16 weeks

Results for this outcome have not been posted.

Other pre-specifiedEXPLORATORY: Confocal Imaging of Tight Junctions and Relationship to LCs in the Epidermis From Non-Lesional Skin

The aim is to assess the effect of dupilumab on non-lesional skin barrier structure and Langerhans cells (LC) by confocal imaging. Inclusion in this exploratory aim is limited to University of Rochester Medical Center study participants.

Time frame:
Days 0 (Prior to treatment), 7 and 21

Results for this outcome have not been posted.

Other pre-specifiedEXPLORATORY: Percent of Coagulase-Negative Staphylococci [CoNS] Isolates That Kill S. Aureus on Lesional and Non-Lesional Skin

The aim is to assess the effect of dupilumab on the function of the skin microbiome (e.g., the ability of Coagulase-negative staphylococci isolates \[CoNS\] to kill S. aureus) in lesional and non-lesional skin.

Time frame:
Day 0 (Prior to treatment), 16 weeks

Results for this outcome have not been posted.

Other pre-specifiedEXPLORATORY: Peripheral Blood Mononuclear Cells (PBMCs) Immunoprofiling

The aim is to assess the effect of dupilumab on PBMC immunoprofiles.Flow cytometry analysis will be performed on PBMCs, using phenotyping panels to identify resting leukocyte populations, as well as T cell responses to antigens and myeloid responses to Toll-like receptor (TLR) ligands.

Time frame:
Days 0 (Prior to treatment), 14 and 28

Results for this outcome have not been posted.

Other pre-specifiedEXPLORATORY: Levels of Serum Biomarkers (e.g. Th2 Biomarkers)

The aim is to assess the effect of dupilumab on serum biomarkers (e.g. T helper type 2 \[Th2\] biomarkers).

Time frame:
Day 0 (Prior to treatment), 16 weeks

Results for this outcome have not been posted.

Other pre-specifiedEXPLORATORY: Levels of Serum Anti-Drug Antibodies (ADA)

The presence of anti-drug antibodies will be assessed and compared between intervention groups.

Time frame:
Day 0 (Prior to treatment), 16 weeks

Results for this outcome have not been posted.

Other pre-specifiedEXPLORATORY: The Presence of Single Nucleotide Polymorphisms (SNPs)

Towards discovery and replication of susceptibility loci in atopic dermatitis pathogenesis.

Time frame:
Day 0 (Prior to treatment)

Results for this outcome have not been posted.

Adverse events

Collected over Up to 182 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dupilumab+Open Label Extension and Follow-Up0/46 (0%)1/46 (2.2%)27/46 (58.7%)
Placebo+Open Label Extension and Follow-Up0/26 (0%)0/26 (0%)17/26 (65.4%)
Most frequent serious events
Most frequent serious events
EventDupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-Up
Intentional overdoseInjury, poisoning and procedural complications1/460/26
Schizoaffective disorder bipolar typePsychiatric disorders1/460/26
Most frequent other events
Showing 10 of 13
Most frequent other events
EventDupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-Up
Dermatitis atopicSkin and subcutaneous tissue disorders7/467/26
EczemaSkin and subcutaneous tissue disorders12/465/26
HeadacheNervous system disorders1/464/26
Upper respiratory tract infectionInfections and infestations7/463/26
NasopharyngitisInfections and infestations6/462/26
ConjunctivitisInfections and infestations4/463/26
FallInjury, poisoning and procedural complications1/463/26
Skin abrasionInjury, poisoning and procedural complications1/463/26
PruritusSkin and subcutaneous tissue disorders4/463/26
Dry eyeEye disorders4/461/26

Baseline characteristics

Modified intent-to-treat (mITT): All participants who were randomized and have Staphylococcus aureus (S. aureus) abundance measured at Day 0 and Day 28.

Age, Continuous
Age, Continuous(years)Dupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-UpTotal
Mean36.6 ± 15.5637.3 ± 15.6136.8 ± 15.47
Sex: Female, Male
Sex: Female, Male(Participants)Dupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-UpTotal
Female17724
Male281947
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-UpTotal
Hispanic or Latino448
Not Hispanic or Latino392261
Unknown or Not Reported202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-UpTotal
American Indian or Alaska Native101
Asian7714
Native Hawaiian or Other Pacific Islander000
Black or African American8311
White211334
More than one race516
Unknown or Not Reported325
Region of Enrollment
Region of Enrollment(Participants)Dupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-UpTotal
United States452671
Body Weight
Body Weight(kilograms (Kg))Dupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-UpTotal
Mean80.7 ± 19.4579.4 ± 18.5880.2 ± 19.01
Height
Height(centimeters (Cm))Dupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-UpTotal
Mean170.9 ± 9.27175.3 ± 11.74172.5 ± 10.38
Body Mass Index (BMI)
Body Mass Index (BMI)(Kg/m^2)Dupilumab+Open Label Extension and Follow-UpPlacebo+Open Label Extension and Follow-UpTotal
Mean27.5 ± 5.6925.7 ± 4.9026.9 ± 5.45

12 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • University of California San Diego
    La Jolla, California 92093, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Stanford University
    Stanford, California 94305, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • University of Florida
    Gainesville, Florida 32611, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Apr 2020, 20 months.

Results were first posted in Jun 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2017
First posted
Jan 4, 2018
StartActual
Jul 25, 2018
Primary completionActual
Apr 3, 2020
CompletionActual
Sep 9, 2020
Results first posted
Jun 14, 2021
Last update
Oct 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03389893
Collaborators
Regeneron Pharmaceuticals, Sanofi, Atopic Dermatitis Research Network, Rho Federal Systems Division, Inc.
Responsible party
Sponsor
First posted
Jan 4, 2018
Start date
Jul 25, 2018
Primary completion
Apr 3, 2020
Completion
Sep 9, 2020
Results posted
Jun 14, 2021
Last update
Oct 4, 2021

Study contacts

Lisa A. Beck, MD
study chair · University of Rochester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion